BBIO
BridgeBio Pharma Inc
NASDAQ: BBIO · HEALTHCARE · BIOTECHNOLOGY
$66.80
-1.11% today
Updated 2026-06-12
Market cap
$13.08B
P/E ratio
—
P/S ratio
22.56x
EPS (TTM)
$-3.74
Dividend yield
—
52W range
$40 – $85
Volume
2.6M
BridgeBio Pharma Inc (BBIO) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$66.80
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$547.00
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.1B | $0.1B | $0.0B | $0.2B | $0.5B | $0.6B | $0.7B | $0.9B | $1.0B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 20.00% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -124.40%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.